Whole-person care

Four in 10 adults will develop cancer in their lifetime,¹ and nearly 70% of cancers have no recommended screening.² Because cancer affects nearly every workforce, employers want to support employees while managing rising cancer-related costs.

We're partnering with Color and GRAIL, leaders in cancer care who reflect our commitment to whole-person care, supporting employees’ physical, emotional and long-term well-being with peace of mind and guidance throughout their entire cancer journey, if diagnosed.

Why employers are investing in cancer solutions

• Earlier detection and faster care can reduce high-cost, late-stage claims
• Cancer navigation helps employees return to work sooner and with more support
• A proactive cancer strategy demonstrates a meaningful commitment to employee well-being

We are offering two solutions for employers to select to fit their employees’ needs.

Cancer Navigation, Support & Screening with Color (Buy-Up)
Employers can choose one, two, or all three of Color’s services:

• Earlier Detection and Prevention, including at-home cervical, prostate, and colorectal screenings and genetic testing for hereditary cancer risk
• Active Treatment Management
• Survivorship Care

Multi-Cancer Early Detection with GRAIL (Buy-Up)

• The Galleri® test is the only MCED test proven through a randomized controlled trial (RCT) to detect cancer earlier and reduce stage IV diagnoses^3,4
• The Galleri® test screens for 50+ cancer types, including those without routine screening^5,6
• Support services for positive test results

Obesity is one of the most expensive chronic conditions affecting 40% of American adults and a leading risk factor for type 2 diabetes and cardiovascular conditions.⁷

GLP-1 medications have become a popular tool in the fight against obesity and type 2 diabetes, but many employers are asking: are these medications delivering long-term value or just short-term results?

Recognizing the importance of long-term, whole-person care, Priority Health has partnered with Virta Health to provide employers with three clinically proven, cost-effective solutions to support their employees.

Carrot offers personalized, inclusive, and compassionate care for every stage of hormonal and reproductive health journeys. Carrot’s person-centered care is there to assist with everything from help with infertility preservation, assisted reproduction, adoption, surrogacy, pregnancy, postpartum, parenting, doula support, menopause, low testosterone, or gender-affirming care.

We’re offering two solutions for employers to choose from to fit their employees needs: Carrot Pro and Carrot Core.

With 50% of Americans suffering with musculoskeletal (MSK) pain¹¹ and 15% of high-cost claims – averaging over $50,000 – stemming from MSK conditions¹², the need for effective pain management is clear. That’s why we’ve partnered with Sword Health.

Our members can now receive personalized treatment right in their homes, freeing them from pain and reducing the financial burden on employers.

Features

Doctors of Physical Therapy + AI

Members work with experienced specialists, each with a Doctor of Physical Therapy degree – never health coaches. Proprietary AI turns Sword clinical experts into superheroes for unmatched member care

Ultra-personalized member experience

Real-time feedback and ongoing dialogue allow members to understand their progress – and enable clinical experts to continuously tailor programs to help members reach their goals.

Industry-leading outcomes & ROI

With more technology patents and clinical results than any company in the industry, Sword delivers unparalleled healthcare cost savings and the highest quality member outcomes.

¹American Cancer Society. Cancer Facts & Figures 2025. American Cancer Society 2025. https://www.cancer.org/research/cancerfacts-statistics/all-cancer-facts-figures/2025-cancer-facts-figures.html

²Business Group on Health. 2025 Employer Health Care Strategy Survey Executive Summary. August 2024. https://www. businessgrouphealth.org/en/Resources/2025-Employer-Health-Care-Strategy-Survey-Executive-Summary

³Swanton C, Johnson P, Round T, et al. NHS-Galleri: primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 30; Chicago. https://grail.com/wp-content/uploads/2026/05/Swanton_ASCO-2026_NHS-Galleri_FINALSlides-05.26.2026.pdf

⁴GRAIL, Inc. Demonstrated performance. [Data on file: GA-2025-0257

⁵Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806

⁶US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results

⁷ Centers for Disease Control and Prevention, 2024
⁸World Health Organization, 2023
⁹ Menopause in the workplace, Carrot 2023

¹⁰Journal of clinical endocrinology & metabolism, 2007

¹¹ https://www.boneandjointburden.org/docs
¹² As reported by Large Employers in 2023, BGoH 

^*Virta defines Type 2 Diabetes Reversal as achieving an A1c below 6.5% without using diabetes medications other than metformin. This is medically termed "remission," as diabetes can return if lifestyle changes aren't maintained.